HYDERABAD, INDIA -- (Marketwired) -- Hetero Group, today announced that it has obtained licensing rights to manufacture and market sofosbuvir and combination drug ledipasvir/sofosbuvir upon approval from Gilead Sciences Inc., USA for 90 countries. Under the said agreement, Hetero is entitled to manufacture and market sofosbuvir and ledipasvir/sofosbuvir in the territories of India, Asia Pacific, Sub-Saharan Africa and other Least Developed Countries. This will expand access of affordable medicines to patients who are infected with chronic hepatitis C in various developing countries. This licensing association marks a significant milestone in ensuring the medicines are accessible globally and thereby addressing the significant public health care issue.
Dr. BPS Reddy, Hetero Group's Chairman commented that, "Hetero is pleased to partner with Gilead on their initiative to bring these life saving medicines to needy populations. Hetero, through this arrangement, will provide access to millions of chronic hepatitis C infected patients at highly competitive prices. Hetero will leverage its R&D and manufacturing capabilities to quickly scale up to meet the huge demand for these medicines."
He also noted that, "Hetero is already an established player in bringing affordable HIV medicines to developing countries and is committed to bringing these hepatitis C medicines quickly to India and other developing countries."
Hetero is a leading global developer, manufacturer, and marketer of pharmaceuticals and their active ingredients. It is the largest privately-owned pharmaceutical company in India. Founded in 1993, Hetero maintains 30 manufacturing facilities across the globe and markets a portfolio of over 200 products in 138 countries. Hetero's commitment to reliability, quality, and value has been a cornerstone since its inception, and the company offers a unique value proposition to its customers in its ability to create efficiencies through vertical integration across the entire manufacturing process. Hetero is credited for its work in bringing affordable HIV medicines to developing countries.